Press release



Western Trust First UK Hospital to Apply Dolphin[®] Quality Assurance System for Radiation Therapy in the UK

Innovative Dolphin[®] system for efficient and safe radiation therapy has been clinically implemented in the hospital's high-quality cancer treatment program in Londonderry

Londonderry, February 07, 2017 – IBA (Ion Beam Applications S.A.), the global high-tech leader in the next generation of proton therapy solutions and radiation therapy quality assurance for the treatment of cancer, announces the **first clinical implementation of Dolphin** Online Ready Patient QA and Monitoring solution **in the United Kingdom**.

With the use of **Dolphin attached to the hospital's TrueBeam**[™] **treatment machine**, the team at the North West Cancer Centre in Londonderry, Northern Ireland, set a new standard for high quality cancer therapy and a more efficient patient Quality Assurance (QA) process. This milestone allows the clinic to offer their patients the latest generation of technology to deliver highest quality radiation therapy treatments.

"With Dolphin we can perform fully independent, measurement-based quality assurance of our most advanced IMRT and VMAT treatments quickly and confidently." says **Dr Andrew Reilly, Head of Radiotherapy Physics at the new North West Cancer Centre, Londonderry**. He continues, "Being so straightforward to use it allows us to plan to the capabilities of the treatment machines, rather than limiting what we do because legacy verification processes cannot keep up. This ensures our clinicians can offer the best possible care to their patients." **Dr Wendy Hyland, Radiotherapy Physicist adds:** "The measurement process is so easy I can spend more time thinking about what the results mean rather than worrying about the measurements themselves."

About the Dolphin System

Dolphin is a complete solution that offers a higher capability to detect and verify possible treatment dose discrepancies compared to conventional QA solutions, thus contributing to a more efficient and safer radiation therapy. This improvement is based on Dolphin's significantly higher treatment dose measurement resolution.

Highly complex IMRT and rotational treatment plans are delivered and measured with the Dolphin transmission detector prior to each patient treatment. A sophisticated TPS-Class software allows **verification of dose deviations in 3D patient anatomy** between the plan and actual delivered dose measured with Dolphin.



Press release | February 7, 2017

IBA Dosimetry GmbH Bahnhofstraße 5 | 90592 Schwarzenbruck | Germany | Tel.: +49 9128 607 0 | Fax: +49 9128 607 10 | VAT REG NO. DE132815519 | Registration Court: Local Court (Amtsgericht) Nürnberg, HRB 4262 | Managing Directors (Geschäftsführer): Olivier Legrain, Robby Plompen | dosimetry-info@iba-group.com | www.iba-dosimetry.com

Press release



The hospital's **patient QA workflow efficiency** is increased with Dolphin's "plug and play" wireless setup and its automatic verification software displaying instant QA results.

The Dolphin solution including the detector and the software is "online ready" and currently used for pre-treatment QA. The system will be capable of **measuring the actual patient treatment dose in online mode, fraction by fraction**. The online capability is currently pending release. For more information visit <u>http://www.iba-dosimetry.com/</u>

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: <u>www.iba-worldwide.com</u>

About Altnagelvin Area Hospital

Altnagelvin Area Hospital is an acute hospital in the North West area of Northern Ireland. The hospital provides a range of services, including a 24-hour Emergency Department and a new cancer centre, offering both chemotherapy and radiotherapy treatments. Altnagelvin Area Hospital is currently undergoing a major redevelopment programme and information regarding location of services, specialty wards will be subject to change over the lifetime of the project.

Media Contact:

Ralf Schira Vice President Marketing IBA Dosimetry ralf.schira@iba-dosimetry.com http://www.iba-dosimetry.com/

Press release | February 7, 2017

IBA Dosimetry GmbH Bahnhofstraße 5 | 90592 Schwarzenbruck | Germany | Tel.: +49 9128 607 0 | Fax: +49 9128 607 10 | VAT REG NO. DE132815519 | Registration Court: Local Court (Amtsgericht) Nürnberg, HRB 4262 | Managing Directors (Geschäftsführer): Olivier Legrain, Robby Plompen | dosimetry-info@iba-group.com | www.iba-dosimetry.com